Does Dr. MARK DETTELBACH have financial conflicts of interest?

Dr. MARK DETTELBACH (M.D.) has received a total of $1,687 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $1,687 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MARK DETTELBACH?

According to CMS Open Payments data, Dr. MARK DETTELBACH received funding from GLAXOSMITHKLINE ($593), REGENERON HEALTHCARE SOLUTIONS ($346), and OPTINOSE US ($300).

Does Dr. MARK DETTELBACH receive research grants or speaking fees?

Dr. MARK DETTELBACH has received $1,687 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MARK DETTELBACH

M.D.Real-Time Hydrated

Specialty: Otolaryngology, Plastic Surgery within the Head & Neck

Practice Location: CHEVY CHASE, MD 20815

NPI Number: 1467425546

LIFETIME INDUSTRY VALUE

$1,687

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. DETTELBACH is a verified Otolaryngology, Plastic Surgery within the Head & Neck practitioner based in CHEVY CHASE, MD.

Between 2021 and 2024, Dr. DETTELBACH had an overall industry promotional and research financial footprint of $1,687 as recorded in the federal CMS Open Payments database.

$1,687 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. DETTELBACH's primary funding source is GLAXOSMITHKLINE, which accounts for $593 (representing 35.1% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GLAXOSMITHKLINE

Rank 1

$593

35.1%

REGENERON HEALTHCARE SOLUTIONS

Rank 2

$346

20.5%

OPTINOSE US

Rank 3

$300

17.8%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.